Clinical Trial

Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This single-center, prospective study and aims to evaluate the efficacy and safety of limertinib combined with etoposide and carboplatin in EGFR-mutant NSCLC patients who develop small-cell lung cancer transformation following progression on EGFR-TKI therapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-25.
Trial Details
NCT Number NCT07001995
Lead Sponsor Hunan Province Tumor Hospital
Conditions Small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer NSCLC
Enrollment 30 participants
Start Date 2026-05-01
Primary Completion 2027-12-30 (estimated)
Study Completion 2028-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-16